Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
AKRO 
Akero Therapeutics Inc (AKRO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/09/2025: AKRO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $56.5
1 Year Target Price $56.5
| 9 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -40.55% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/09/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.50B USD | Price to earnings Ratio - | 1Y Target Price 56.5 |
Price to earnings Ratio - | 1Y Target Price 56.5 | ||
Volume (30-day avg) 12 | Beta -0.4 | 52 Weeks Range 21.34 - 58.40 | Updated Date 12/20/2025 |
52 Weeks Range 21.34 - 58.40 | Updated Date 12/20/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.75 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -22.63% | Return on Equity (TTM) -34.53% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3762368919 | Price to Sales(TTM) - |
Enterprise Value 3762368919 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -6.77 | Shares Outstanding 82324445 | Shares Floating 71105539 |
Shares Outstanding 82324445 | Shares Floating 71105539 | ||
Percent Insiders 1.46 | Percent Institutions 112.47 |
Upturn AI SWOT
Akero Therapeutics Inc
Company Overview
History and Background
Akero Therapeutics Inc. was founded in 2017. The company is a clinical-stage biotechnology company focused on developing transformative therapies for serious metabolic diseases, particularly nonalcoholic steatohepatitis (NASH). Its evolution has been driven by the advancement of its lead product candidate through clinical trials and strategic partnerships within the pharmaceutical industry.
Core Business Areas
- Therapeutic Development: Akero Therapeutics Inc. is dedicated to the research and development of novel drug candidates to address significant unmet medical needs in metabolic diseases. Their primary focus is on developing treatments that can effectively target the underlying mechanisms of these diseases.
Leadership and Structure
Akero Therapeutics Inc. is led by a management team with extensive experience in biotechnology and drug development. The company operates with a typical biotech organizational structure, emphasizing research and development, clinical operations, and regulatory affairs.
Top Products and Market Share
Key Offerings
- Product Name 1: Efaroxinal (AKR-001) - Efaroxinal is Akero's lead investigational therapy. It is a non-nontranscriptional activator of FGF21, designed to address the multiple metabolic pathways implicated in NASH, including steatosis, inflammation, and fibrosis. Currently in Phase 2b clinical trials. Competitors include various pharmaceutical companies developing therapies for NASH, such as Madrigal Pharmaceuticals (Madrigal), Intercept Pharmaceuticals (Intercept), and Gilead Sciences (Gilead).
Market Dynamics
Industry Overview
The biotechnology industry, particularly the segment focused on metabolic diseases like NASH, is highly dynamic and competitive. It is characterized by significant R&D investment, a lengthy drug development process, and a strong focus on innovation to address complex diseases with limited treatment options.
Positioning
Akero Therapeutics Inc. is positioned as a clinical-stage biotechnology company with a promising lead candidate for NASH. Its competitive advantage lies in its scientific approach to targeting key metabolic pathways implicated in the disease. However, it faces significant competition from larger pharmaceutical companies with established R&D pipelines and resources.
Total Addressable Market (TAM)
The Total Addressable Market for NASH therapies is substantial, estimated to be in the tens of billions of dollars annually due to the high prevalence of the disease globally. Akero Therapeutics Inc. aims to capture a significant portion of this market with its potentially first-in-class therapy. Its positioning with respect to this TAM is as a developing player aiming to address a critical unmet need.
Upturn SWOT Analysis
Strengths
- Strong scientific rationale for its lead candidate.
- Focus on a significant unmet medical need (NASH).
- Experienced management team.
Weaknesses
- Clinical-stage company with no approved products.
- Reliance on successful clinical trial outcomes.
- Limited financial resources compared to large pharmaceutical companies.
Opportunities
- Growing prevalence of NASH globally.
- Potential for breakthrough therapy designation.
- Strategic partnerships and collaborations.
- Advancements in diagnostic tools for NASH.
Threats
- Clinical trial failures or delays.
- Emergence of competing therapies.
- Regulatory hurdles and stringent approval processes.
- Pricing and reimbursement challenges.
Competitors and Market Share
Key Competitors
- Madrigal Pharmaceuticals (MDGL)
- Intercept Pharmaceuticals (ICPT)
- Gilead Sciences (GILD)
Competitive Landscape
Akero Therapeutics Inc. faces intense competition in the NASH market. While Efaroxinal aims to address multiple aspects of NASH, competitors like Madrigal Pharmaceuticals have progressed further with their lead candidates. Akero's advantage lies in its scientific approach, but it faces challenges in terms of clinical trial timelines and the financial muscle of larger, established players.
Growth Trajectory and Initiatives
Historical Growth: Historical growth for Akero Therapeutics Inc. has been driven by its progression through preclinical and early-stage clinical development. Key milestones have included successful IND submissions and the initiation of clinical trials. Growth has also been fueled by successful fundraising rounds.
Future Projections: Future growth projections are highly dependent on the successful outcomes of its ongoing clinical trials, particularly for Efaroxinal (AKR-001). Analyst estimates would focus on potential peak sales if the drug is approved and market penetration.
Recent Initiatives: Recent initiatives likely include the advancement of Efaroxinal into later-stage clinical trials, potential strategic partnerships, and ongoing efforts to secure financing for its development programs.
Summary
Akero Therapeutics Inc. is a clinical-stage biotech company with a promising lead candidate for NASH. Its strengths lie in its scientific approach and the significant unmet need it addresses. However, it faces considerable risks due to its lack of approved products, reliance on clinical trial success, and intense competition. Continued progress in clinical trials and successful fundraising are crucial for its future.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company press releases and SEC filings (e.g., 10-K, 10-Q)
- Industry research reports
- Financial news outlets
- Biotechnology databases
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute investment advice. Investors should conduct their own due diligence before making any investment decisions. Financial data and market share estimations are subject to change and may vary depending on the source and methodology.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Akero Therapeutics Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2019-06-20 | President, CEO & Director Dr. Andrew Cheng M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 74 | Website https://akerotx.com |
Full time employees 74 | Website https://akerotx.com | ||
Akero Therapeutics, Inc. engages in developing transformational treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Therapeutics, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California. As of December 9, 2025, Akero Therapeutics, Inc. operates as a subsidiary of Novo Nordisk A/S.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.